Scripps proton beam radiation therapy center files for bankruptcy

We have long been concerned that the number of proton beam radiation therapy (PBRT) centers being built here in the USA was way higher than could be justified by the real demand for such services. … READ MORE …

Genomic profiling of prostate cancer

The “New” Prostate Cancer InfoLink has been made aware of an interesting new initiative under development at The Broad Institute up in Boston. … READ MORE …

More on the new guidelines for treatment of localized prostate cancer

So your sitemaster was able to spend a while this morning reading through the full 56 pages of the new AUA/ASTRO/SUO guidelines on the treatment of localized prostate cancer. … READ MORE …

CureTalk on genomic testing and precision medicine

For interested readers, there will be a CureTalk this evening on precision medicine and the role of genetic/genomic testing in the selection of appropriate forms of treatment. It will not be prostate cancer-specific, but its role in prostate cancer will be addressed. … READ MORE …

A piece of good news from Washington, DC

The “New” Prostate Cancer InfoLink has heard that, as part of the final resolution of the US federal budget for fiscal year 2017 (which passed the Senate yesterday), there has been a $10 million increase in funding for the Prostate Cancer Research Program (PCRP) within the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP). … READ MORE …

Dr. Charles Ryan’s blogs on the UroToday web site

Many readers may be interested in knowing that Dr. Charles Ryan (a medical oncologist at the University of California, San Francisco) is now blogging about prostate cancer in his capacity as one of the “centers of excellence” editors for the UroToday web service. … READ MORE …

An update to the PrEvENT trial in England

The Prostate Cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) has been ongoing in England since August 2014 and is an important and serious exploration of how diet and exercise may affect the outcomes of men who are treated for prostate cancer. … READ MORE …